{"id":579878,"date":"2010-05-26T18:14:36","date_gmt":"2010-05-26T22:14:36","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=81925"},"modified":"2010-05-26T18:14:36","modified_gmt":"2010-05-26T22:14:36","slug":"la-jolla-pharmaceutical-revives-with-6m-financing","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/579878","title":{"rendered":"La Jolla Pharmaceutical Revives With $6M Financing"},"content":{"rendered":"\n
Life Sciences<\/a>, Financing<\/a>, Lupus<\/a><\/div>\n

\t\tBruce V. Bigelow wrote:<\/strong><\/p>\n

Like a scene from a Monty Python skit, a San Diego biotech left for dead has announced plans for a new financing—and says it has revived interest in its experimental drug for treating Lupus of the kidneys. The company halted work<\/a> on the drug in early 2009.\u00a0 In a statement <\/a>yesterday, La Jolla Pharmaceutical disclosed plans to raise as much as $16.3 million to evaluate potential various opportunities, including Riquent, its drug for Lupus nephritis. The San Diego Union-Tribune reports today<\/a> that La Jolla Pharmaceutical found institutional investors to commit up to $6 million toward efforts to restart its business. The biotech could not get enough shareholders to vote on a liquidation <\/a>plan last year, and withdrew from a planned merger<\/a> in March.<\/p>\n


<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

UNDERWRITERS AND PARTNERS
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t<\/p>\n

\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t<\/a>
\n\t\t\t\t\t\t\t\t\t

\n

\n\"\"<\/a>
\n\"\"\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, Financing, Lupus Bruce V. Bigelow wrote: Like a scene from a Monty Python skit, a San Diego biotech left for dead has announced plans for a new financing—and says it has revived interest in its experimental drug for treating Lupus of the kidneys. The company halted work on the drug in early 2009.\u00a0 […]<\/p>\n","protected":false},"author":5423,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-579878","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/579878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/5423"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=579878"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/579878\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=579878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=579878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=579878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}